Skip to main content
. Author manuscript; available in PMC: 2014 Oct 2.
Published in final edited form as: Oncogene. 2013 Jul 22;33(25):3325–3333. doi: 10.1038/onc.2013.287

Figure 1.

Figure 1

Survival, metastasis and pERK1/2 staining of pancreatic tumours in different p63/(mutant) p53 mouse models. (a) The overall survival of Pdx1-Cre, LSL-KrasG12D/ + (yellow), Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ + (blue), Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/+, TAp63fl/fl(red, n =21), Pdx1-Cre, LSL-KrasG12D/ +, TAp63fl/fl(cyan) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53172H/ + (green) mice was plotted in a Kaplan–Meier survival curve. Mice that succumbed to the disease before developing pancreatic cancer are shown as crossmarks on the survival curves. Significant differences in survival were detected between Pdx1-Cre, LSL-KrasG12D/ + mice (yellow) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ + mice (blue) (P =0.000), between Pdx1-Cre, LSL-KrasG12D/ + (yellow) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53R172H/ + (green) (P =0.000), and between Pdx1-Cre, LSL-KrasG12D/ + (yellow) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ +, TAp63fl/fl (red) (P =0.000) in a log-rank test. Significant differences in survival were also detected between Pdx1-Cre, LSL-KrasG12D/ +, TAp63fl/fl mice (cyan) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ + mice (blue) (P =0.000), between Pdx1-Cre, LSL-KrasG12D/ +, TAp63fl/fl (cyan) and Pdx1-Cre, LSL-KrasG12D/ +, LSL-Trp53R172H/ + (green) (P =0.000), and between Pdx1-Cre, LSL-KrasG12D/ +, TAp63fl/fl (cyan) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/+, TAp63fl/fl (red) (P =0.000) in a log-rank test. There was no significant difference in survival between Pdx1-Cre, LSL-KrasG12D/ + (yellow) and Pdx1-Cre, LSL-KrasG12D/ +, TAp63fl/fl (cyan) mice (P =0.697), or between Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ + (blue) and Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ +, TAp63fl/fl (red) mice (P =0.235). (b) Metastases in Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ +, TAp63fl/fl mice in the lymph nodes (left), liver (middle) and lung (right). (c) pERK1/2 staining in the pancreatic tumours of Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ +, Pdx1-Cre, LSL-KrasG12D/ +, Trp53fl/ +, TAp63fl/fl and Pdx1-Cre, LSL-KrasG12D/ +, LSL-Trp53172H/ + mice.

HHS Vulnerability Disclosure